Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
Status:
Completed
Trial end date:
2020-12-28
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of AB002 (E-WE thrombin) in patients with end
stage renal disease on chronic hemodialysis. Two dose levels will be evaluated in two
cohorts. Within each cohort the patients will be randomized to receive either AB002 (E-WE
thrombin) or placebo (at a ratio of 2:1 active: placebo).